These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 33309149)

  • 1. Assessment of the radiation exposure of relatives and caregivers of patients treated with Ra-223 - Results of a German multicenter study.
    Wanke C; Pinkert J; Szermerski B; Geworski L
    Z Med Phys; 2021 Feb; 31(1):58-64. PubMed ID: 33309149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extraction of
    Großer OS; Wissel H; Wallbaum T; Genseke P; Kupitz D; Ricke J; Ruf J; Amthauer H
    Nuklearmedizin; 2017 Jun; 56(3):69-72. PubMed ID: 28383088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Excretion and whole-body retention of radium-223 dichloride administered for the treatment of bone metastases from castration resistant prostate cancer.
    Pratt BE; Hindorf C; Chittenden SJ; Parker CC; Flux GD
    Nucl Med Commun; 2018 Feb; 39(2):125-130. PubMed ID: 29189490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting (223)Ra-dichloride.
    Pacilio M; Ventroni G; De Vincentis G; Cassano B; Pellegrini R; Di Castro E; Frantellizzi V; Follacchio GA; Garkavaya T; Lorenzon L; Ialongo P; Pani R; Mango L
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):21-33. PubMed ID: 26266887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why.
    Gallicchio R; Mastrangelo PA; Nardelli A; Mainenti PP; Colasurdo AP; Landriscina M; Guglielmi G; Storto G
    Tumori; 2019 Oct; 105(5):367-377. PubMed ID: 31096849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic changes of bone metastasis predict bone-predominant status to benefit from radium-223 dichloride for patients with castration-resistant prostate cancer.
    Hashimoto K; Miyoshi Y; Shindo T; Hori M; Tsuboi Y; Kobayashi K; Fukuta F; Tanaka T; Miyamoto S; Maehana T; Okada M; Nishiyama N; Yanase M; Kato R; Hotta H; Kunishima Y; Takahashi A; Hinotsu S; Sakata KI; Kitamura H; Uemura H; Masumori N
    Cancer Med; 2020 Nov; 9(22):8579-8588. PubMed ID: 32964674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Alpha emitter radium-223 dichloride: new therapy in castration-resistant prostate cancer with symptomatic bone metastases].
    Heinzer H; König F; Klutmann S
    Urologe A; 2014 Apr; 53(4):519-23. PubMed ID: 24604017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer.
    Carrasquillo JA; O'Donoghue JA; Pandit-Taskar N; Humm JL; Rathkopf DE; Slovin SF; Williamson MJ; Lacuna K; Aksnes AK; Larson SM; Scher HI; Morris MJ
    Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1384-93. PubMed ID: 23653243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Introduction of the targeted alpha therapy (with Radium-223) into clinical practice in Japan: learnings and implementation.
    Hosono M; Ikebuchi H; Nakamura Y; Yanagida S; Kinuya S
    Ann Nucl Med; 2019 Mar; 33(3):211-221. PubMed ID: 30484260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.
    Uemura H; Uemura H; Nagamori S; Wakumoto Y; Kimura G; Kikukawa H; Yokomizo A; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Akagawa T; Matsubara N
    Int J Clin Oncol; 2019 May; 24(5):557-566. PubMed ID: 30875000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of pre-treatment variables on the completion of
    Lavelli V; Nappi AG; Caputo P; Asabella AN; Fanelli M; Sardaro A; Altini C; Ferrari C; Rubini G
    Hell J Nucl Med; 2019; 22 Suppl 2():153-163. PubMed ID: 31802056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase 1, Open-Label Study of the Biodistribution, Pharmacokinetics, and Dosimetry of 223Ra-Dichloride in Patients with Hormone-Refractory Prostate Cancer and Skeletal Metastases.
    Chittenden SJ; Hindorf C; Parker CC; Lewington VJ; Pratt BE; Johnson B; Flux GD
    J Nucl Med; 2015 Sep; 56(9):1304-9. PubMed ID: 26182965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiation safety considerations for the use of ²²³RaCl₂ DE in men with castration-resistant prostate cancer.
    Dauer LT; Williamson MJ; Humm J; O'Donoghue J; Ghani R; Awadallah R; Carrasquillo J; Pandit-Taskar N; Aksnes AK; Biggin C; Reinton V; Morris M; St Germain J
    Health Phys; 2014 Apr; 106(4):494-504. PubMed ID: 24562070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.
    Sartor O; Coleman R; Nilsson S; Heinrich D; Helle SI; O'Sullivan JM; Fosså SD; Chodacki A; Wiechno P; Logue J; Widmark A; Johannessen DC; Hoskin P; James ND; Solberg A; Syndikus I; Vogelzang NJ; O'Bryan-Tear CG; Shan M; Bruland ØS; Parker C
    Lancet Oncol; 2014 Jun; 15(7):738-46. PubMed ID: 24836273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases.
    Yoshida K; Kaneta T; Takano S; Sugiura M; Kawano T; Hino A; Yamamoto T; Shizukuishi K; Kaneko M; Zurth C; Inoue T
    Ann Nucl Med; 2016 Aug; 30(7):453-60. PubMed ID: 27272279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose estimation after a mixed field exposure: Radium-223 and intensity modulated radiotherapy.
    Bastiani I; McMahon SJ; Turner P; Redmond KM; McGarry CK; Cole A; O'Sullivan JM; Prise KM; Ainsbury L; Anderson R
    Nucl Med Biol; 2022; 106-107():10-20. PubMed ID: 34968973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radium-223 dichloride: a novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases.
    McGann S; Horton ER
    Ann Pharmacother; 2015 Apr; 49(4):469-76. PubMed ID: 25573268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary.
    Kluetz PG; Pierce W; Maher VE; Zhang H; Tang S; Song P; Liu Q; Haber MT; Leutzinger EE; Al-Hakim A; Chen W; Palmby T; Alebachew E; Sridhara R; Ibrahim A; Justice R; Pazdur R
    Clin Cancer Res; 2014 Jan; 20(1):9-14. PubMed ID: 24190979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mRNA and small RNA gene expression changes in peripheral blood to detect internal Ra-223 exposure.
    Ostheim P; Miederer M; Schreckenberger M; Nestler T; Hoffmann MA; Lassmann M; Eberlein U; Barsegian V; Rump A; Majewski M; Port M; Abend M
    Int J Radiat Biol; 2022; 98(5):900-912. PubMed ID: 34882512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radium Ra 223 dichloride in castration-resistant prostate cancer.
    Joung JY; Ha YS; Kim IY
    Drugs Today (Barc); 2013 Aug; 49(8):483-90. PubMed ID: 23977665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.